Differential risk of cardiovascular complications in patients with type-2 diabetes mellitus in Ghana: A hospital-based cross-sectional study
Open Access
- 6 February 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0302912
Abstract
Aim: To characterize clinically relevant subgroups of patients with type-2 diabetes mellitus (T2DM) based on adiposity, insulin secretion, and resistance indices. Methods: A cross-sectional study was conducted at Eastern Regional Hospital in Ghana from July to October 2021 to investigate long-term patients with T2DM. To select participants, a systematic random sampling method was employed. Demographic data was collected using a structured questionnaire and fasting blood samples were taken to measure glycemic and lipid levels. Blood pressure and adiposity indices were measured during recruitment. The risk of cardiovascular disease (CVD) was defined using Framingham scores and standard low-density lipoprotein thresholds. To analyze the data, k-means clustering algorithms and regression analysis were used. Results: The study identified three groups in female patients according to body mass index, relative fat mass, glycated hemoglobin, and triglyceride-glucose index. These groups included the obesity-related phenotype, the severe insulin resistance phenotype, and the normal weight phenotype with improved insulin resistance. Among male patients with T2DM, two groups were identified, including the obesity-related phenotype with severe insulin resistance and the normal weight phenotype with improved insulin sensitivity. The severe insulin resistance phenotype in female patients was associated with an increased risk of high CVD (OR = 5.34, 95%CI:2.11–13.55) and metabolic syndrome (OR = 7.07; 95%CI:3.24–15.42). Among male patients, the obesity-related phenotype with severe insulin resistance was associated with an increased intermediate (OR = 21.78, 95%CI:4.17–113.78) and a high-risk CVD (OR = 6.84, 95%CI:1.45–32.12). Conclusions: The findings highlight significant cardiometabolic heterogeneity among T2DM patients. The subgroups of T2DM patients characterized by obesity and/or severe insulin resistance with or without poor glycemic control, have increased risk of CVD. This underscores the importance of considering differences in adiposity, insulin secretion, and sensitivity indices when making clinical decisions for patients with T2DM.Keywords
This publication has 58 references indexed in Scilit:
- Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general populationEuropean Journal of Internal Medicine, 2023
- Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose indexDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2022
- Triglyceride–glucose index associates with incident heart failure: A cohort studyDiabetes & Metabolism, 2022
- Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trialDiabetologia, 2021
- The triglyceride–glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistanceDiabetes Research and Clinical Practice, 2021
- Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adultsThe Lancet, 2021
- Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial dataThe Lancet Diabetes & Endocrinology, 2019
- Relative fat mass (RFM) as a new estimator of whole-body fat percentage ─ A cross-sectional study in American adult individualsScientific Reports, 2018
- Triglycerides and glucose index: A useful indicator of insulin resistanceEndocrinología y Nutrición (English Edition), 2014
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsJACC, 2014